8:28
This video explores the LEVELUP SWITCH study, a pivotal phase 4 trial assessing the switch from injectable dupilumab to oral upadacitinib in patients with moderate to severe atopic dermatitis. It highlights the study's unique design, significant efficacy outcomes, and safety results, emphasizing the importance of timely intervention and treatment adjustments for improved patient care.
Produced with Vocal Video